These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 8408731)
1. Localization of drug release sites from an oral sustained-release formulation of 5-ASA (Pentasa) in the gastrointestinal tract using gamma scintigraphy. Hardy JG; Harvey WJ; Sparrow RA; Marshall GB; Steed KP; Macarios M; Wilding IR J Clin Pharmacol; 1993 Aug; 33(8):712-8. PubMed ID: 8408731 [TBL] [Abstract][Full Text] [Related]
2. Release of 5-ASA from Pentasa in patients with Crohn's disease of the small intestine. Larouche J; Morais J; Picard M; Lambert C; Spénard J; Landriault H; Kennedy G; Poitras P Aliment Pharmacol Ther; 1995 Jun; 9(3):315-20. PubMed ID: 7654894 [TBL] [Abstract][Full Text] [Related]
3. Gastrointestinal spread of oral prolonged-release mesalazine microgranules (Pentasa) dosed as either tablets or sachet. Wilding IR; Kenyon CJ; Hooper G Aliment Pharmacol Ther; 2000 Feb; 14(2):163-9. PubMed ID: 10651656 [TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal transit of an enteric-coated delayed-release 5-aminosalicylic acid tablet. Hardy JG; Healey JN; Lee SW; Reynolds JR Aliment Pharmacol Ther; 1987 Jun; 1(3):209-16. PubMed ID: 2979223 [TBL] [Abstract][Full Text] [Related]
5. Topical and systemic availability of 5-aminosalicylate: comparisons of three controlled release preparations in man. Christensen LA; Fallingborg J; Abildgaard K; Jacobsen BA; Sanchez G; Hansen SH; Bondesen S; Hvidberg EF; Rasmussen SN Aliment Pharmacol Ther; 1990 Oct; 4(5):523-33. PubMed ID: 2129640 [TBL] [Abstract][Full Text] [Related]
6. 5-aminosalicylic acid release from a new controlled-release mesalazine formulation during gastrointestinal transit in healthy volunteers. Brunner M; Lackner E; Exler PS; Fluiter HC; Kletter K; Tschurlovits M; Dudczak R; Eichler HG; Müller M Aliment Pharmacol Ther; 2006 Jan; 23(1):137-44. PubMed ID: 16393291 [TBL] [Abstract][Full Text] [Related]
8. Concentrations of 5-ASA and Ac-5-ASA in human ileocolonic biopsy homogenates after oral 5-ASA preparations. De Vos M; Verdievel H; Schoonjans R; Praet M; Bogaert M; Barbier F Gut; 1992 Oct; 33(10):1338-42. PubMed ID: 1446856 [TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of 5-aminosalicylic acid from a controlled release preparation and an azo-bond preparation. Christensen LA; Fallingborg J; Jacobsen BA; Abildgaard K; Rasmussen HH; Hansen SH; Rasmussen SN Aliment Pharmacol Ther; 1994 Jun; 8(3):289-94. PubMed ID: 7918923 [TBL] [Abstract][Full Text] [Related]
10. Release of 5-aminosalicylate from an MMX mesalamine tablet during transit through a simulated gastrointestinal tract system. Tenjarla S; Romasanta V; Zeijdner E; Villa R; Moro L Adv Ther; 2007; 24(4):826-40. PubMed ID: 17901032 [TBL] [Abstract][Full Text] [Related]
11. Delivery and fate of oral mesalamine microgranules within the human small intestine. Layer PH; Goebell H; Keller J; Dignass A; Klotz U Gastroenterology; 1995 May; 108(5):1427-33. PubMed ID: 7729635 [TBL] [Abstract][Full Text] [Related]
13. Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. Yu A; Baker JR; Fioritto AF; Wang Y; Luo R; Li S; Wen B; Bly M; Tsume Y; Koenigsknecht MJ; Zhang X; Lionberger R; Amidon GL; Hasler WL; Sun D Mol Pharm; 2017 Feb; 14(2):345-358. PubMed ID: 28009518 [TBL] [Abstract][Full Text] [Related]
14. Distal ileum and colon: targeted sites for 5-ASA release. Devane J; Mulligan S; Martin M Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():300-3. PubMed ID: 1820897 [TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation. Brunner M; Assandri R; Kletter K; Tschurlovits M; Corrado ME; Villa R; Eichler HG; Müller M Aliment Pharmacol Ther; 2003 Feb; 17(3):395-402. PubMed ID: 12562452 [TBL] [Abstract][Full Text] [Related]
16. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man. Christensen LA Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142 [TBL] [Abstract][Full Text] [Related]
17. Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease. Healey JN Scand J Gastroenterol Suppl; 1990; 172():47-51. PubMed ID: 2353171 [TBL] [Abstract][Full Text] [Related]
18. In vitro and human pharmacoscintigraphic evaluation of an oral 5-ASA delivery system for colonic release. Foppoli A; Maroni A; Moutaharrik S; Melocchi A; Zema L; Palugan L; Cerea M; Gazzaniga A Int J Pharm; 2019 Dec; 572():118723. PubMed ID: 31628978 [TBL] [Abstract][Full Text] [Related]
19. 5-Aminosalicylic acid in patients with an ileo-rectal anastomosis. A comparison of the fate of sulfasalazine and Pentasa. Bondesen S; Tage-Jensen U; Jacobsen O; Hansen SH; Rasmussen SN; Hvidberg EF Eur J Clin Pharmacol; 1986; 31(1):23-6. PubMed ID: 2877884 [TBL] [Abstract][Full Text] [Related]
20. Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds. Rijk MC; van Schaik A; van Tongeren JH Scand J Gastroenterol; 1988 Jan; 23(1):107-12. PubMed ID: 2894070 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]